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Malaria, a vector born infectious disease, 
impinges on approximately more than 500 
million per annum with deaths of more than a 
million, mostly in Africa [1]. The bitter truth to 
find out is that there occurs a death of a child 
in each 30 seconds due to malaria [2]. Apart 
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Abstract: An efficient strategy for the syntheses of highly diverse benzimidazoles in exceptional yields via 
post Ugi reactions has been described. In our methodology we have utilized isocyanide based Ugi-reaction 
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reference compound. Among these compounds, three of them (8b), (8c), (8d) were found to be most po-
tent towards antimalarial activity. The synthesized hybrids were examined for their purity with the help of 
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Mass studies, NMRs (1H and 13C) and FT-IR. 
Keywords: Antimalarial, benzimidazole, chloroquine, synthesized hybrids and post Ugi reactions.
Anshu Dandiaa*, Pankaj Potliaa, Irfan Khanb, Vivek Kumarc, Ved Prakash Vermad, Manvika Kar-
natakd, Anupam Dhasmanae, Shashi Pandeyf, Tarun Shrimali,g* Vijay Parewaa, Shahnawaz Khanh* 
and Jaybir Singhi*
aCenter of Advanced Studies, Department of Chemistry, University of Rajasthan, Jaipur-302004
bCo-Ordination Chemistry Laboratory, Department of Chemistry, Mohan Lal Sukhadia
University, Udaipur (Rajasthan) India.
cHuman Genome and Stem-cell Center (HUG-CELL), Department of Genetics & Evolutionary Biology, Institute of 
Biosciences, University of São Paulo, Butanta, 05,508,090 -São Paulo, SP – Brazil
dDepartment of Chemistry, Banasthali Vidyapith Newai – 304022
eHimalayan School of Bio sciences, Swami Rama Himalayan University, Dehradun, India  & Department of Immu-
nology and Microbiology School of Medicine, University of Texas Rio Grande Valley, Mcallen, USA. 
fDepartment of Chemistry, R.D. College, Sheikhpura, ( constituent college of munger University,munger)Bihar, 
811105
gR&D Cell, J.R.N. Rajasthan Vidyapeeth (Deemed to be University), Udaipur (Raj.), India.
hDepartment of Chemistry, J.R.N. Rajasthan Vidyapeeth (Deemed to be University), Udaipur (Raj.), India. 
iDepartment of pharmacy, Dr. B. R. Ambedkar University, Agra (India) 282002 
Email - dranshudandia@yahoo.co.in* jbmpharm@gmail.com  * khancdri@gmail.com
Received 2019; Accepted 2019
ISSN: 2249 –4820RESEARCH PAPER
CHEMISTRY & BIOLOGY INTERFACE
An official Journal of ISCB, Journal homepage; www.cbijournal.com
Chemistry & Biology Interface, 2019, 9, 4, 216-224
Chemistry & Biology Interface Vol. 9 (4), July – August 2019217
Chemistry & Biology Interface, 2019, 9, 4, 216-224
from the morbidity and mortality, malaria 
imparts a great economic burden on the affected 
regions [3-4]. The scenario is getting worse 
with the speedy and wide-spread of multidrug-
resistant parasites all over the world. Malaria 
is distributed chiefly in the warm tropical 
regions mainly Africa, South-east Asia, Pacific 
Islands, India, Central and Southern America 
[5]. The main agent or causative agent of this 
dreadful malaria is a protozoan parasite of 
genus Plasmodium. Out of 100s so far known 
species, only four species namely P. falciparum, 
P. ovale, P. vivax, and P. malariae are found to 
be infective to human beings [6].
Quinine and artemisinin both have worked as 
an efficient scaffold for the formation of newer 
valuable antimalarials. In addition researchers 
have reported novel synthetic compounds with 
unique scaffolds as antimalarials [7]. This 
literature review will briefly discuss about 
history of antimalarial chemotherapy[8]. It also 
covers structurally simple synthetic analogues 
of these natural products and novel synthetic 
compounds with distinctive scaffolds which 
have influenced or have potential to influence 
the course of malarial chemotherapy.
Due to development of enormous number of 
problems associated with the earlier natural 
alkaloids; like spread of resistance against 
former drugs, side-effects, haemolysis, toxicity 
and many more, it was perceived to research 
more on the synthetic moieties to develop 
newer, safer, and more effective drugs. After 
going through the literature of the development 
of the various antimalarial drugs prevalent so 
far; one can perceive that different structures 
possess different biological activities and also 
with change either in the core moiety, derivative 
or side chain, there emerges significantly varied 
characteristics from the parent moiety. Thus 
various derivations in any synthetic moiety may 
lead to enhancement in its biological activities.
Also, recent advancements in drug discovery 
have shown that by combining two or more 
pharmacophoric active moieties into one hybrid 
through molecular hybridization approach 
leads to more potent and progressive hybrid 
than the parent drug [9]. Amid heterocyclic 
structures for their exploration in bioactive 
drugs, the benzimidazole scheme is moderately 
widespread and is often called as ‛privileged’, 
exhibiting wide range of diverse biological 
activities depending upon the changing groups 
or pharmacophoric moieties on the core 
structure, including anti-cancer, bactericidal, 
fungicidal, analgesic, anti-viral properties, 
mainly as antimalarial, cardiovascular potent 
and as inhibitors of HIV-1 infectivity [10-16]. 
(Fig. 2)
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Fig. 2: Potent therapeutic activities of benzimidazole ring in varied fields.
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Thus, benzimidazole moiety has been extensively 
studied as an important nitrogen containing 
heterocycle [17]; also as a promising drug in 
the treatment of several diseases including 
diabetes, infertility, epilepsy, as analgesic, anti-
inflammatory, antibacterial, antihistaminic, anti 
ulcer, AT1 receptor antagonists, antifungal, 
antiparasitic, anthelmintics, antiviral agent etc. 
[18-20]  (Fig. 3). 
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Fig. 3: Some potent clinically important 
drugs containing benzimidazole as the core 
moiety.
In persistence of our studies directed towards 
searching simpler, competent and dexterous 
synthetic procedures for assimilation 
of biologically imperative heterocyclic 
compounds, we have chosen benzimidazoles 
as the target molecule, subjected to addition of 
other biologically active pharmacophoric sites 
to form efficient antimalarial hybrids. They 
possess unique properties as the moiety shows 
both acidic and basic characteristics due to NH 
group which make it a perfect base for salt 
formation. 
Since the chemotherapy against neglected 
tropical (NTDs) diseases has not developed 
as yet at a sufficient level, the search for more 
efficient and protected drugs is still desirable. 
Attention was focussed on the development 
of synthesis of substituted benzimidazoles 
derivatives as they have been extensively 
employed in the area of pharmaceuticals. These 
potentialities have led them to be explored more 
through different synthetic methodologies. A 
vigilant analysis revealed that most of these 
methodologies endured serious drawbacks 
which limit their efficacy and applicability at 
large scale production. 
Recently, multicomponent reactions (MCRs) 
have been emerged as a powerful tool for the 
synthesis of biologically important heterocycles 
[21]. Among these MCRs, the isocyanide 
based multicomponent reactions have made 
their way as the most imperative ones [22]. 
Their significance for library synthesis can be 
attributed to their fast, efficient time competent 
one pot synthetic procedure. Among MCRs, 
most accepted strategy is the Ugi reaction 
where an isocyanide, amine, acid and aldehyde 
combine in a one-pot approach to form a hybrid 
of N-substituted acyl aminoamide [22].
With this strategy in mind, and in continuance of 
our research attention towards the advancement 
of new greener approaches for biologically 
active heterocyclic moiety; we have developed 
an efficient microwave irradiated, time-
competent efficient amalgamation of novel 
hybrids of biologically vital benzimidazoles, 
amidic and various aromatic moieties. All the 
hybrids were screened for their antimalarial 
activity against the 3D7 P. falciparum strain 
(Scheme 1).
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Scheme 1: Microwave assisted synthesis 
of derivatives of benzimidazole including 
pharmacophoric moieties of boc-protected 
o-phenylenediamine, benzoic acid, 
benzaldehyde and tert-butyl isocyanide.
Experimental
All reagents and solvents were purchased 
from commercial sources and used without 
purification. NMR spectra were recorded 
with 200, 300, 400 MHz spectrometers for 1H 
NMR and 50, 75, 100 MHz for 13C NMR on 
Bruker Supercon Magnet Avance DRX-300 
spectrometers in deuterated solvents with TMS 
as internal reference (chemical shifts δ in ppm, 
coupling constant J in Hz.). Multiplicities are 
reported as follows: singlet (s), doublet (d), 
triplet (t), multiplet (m), and broad singlet (br 
s). Mass spectra and HRMS were taken in the 
ESI positive ion mode. Microwave reactions 
were conducted using a Biotage Initiator in 
10-mL glass tubes, sealed with Teflon septum 
and placed in the microwave cavity. The 
reaction progress was monitored by thin layer 
chromatography (TLC) on pre-coated silica gel 
plates. Column chromatography was performed 
over Merck silica gel (230-400 flash). All 
compounds were characterized by TLC, 1H 
NMR and 13C NMR, MS and HRMS. 
SPECTRAL STUDIES
The structures of all the compounds 8(a-g) have 
been explicated using various analytic studies 
like mass analysis, both the NMRs of 1H and 13C 
together with the assistance of IR. Lets take an 
example of compound 8d as a reference.
A pale yellow solid was isolated after 
crystallization whose melting point was 
calculated as 140-142oC. When it was subjected 
to IR radiations, it showed important absorptions 
peaks which denoted particular bond stretching 
for example absorptions were noted at 3291 
(Aliphatic N-H stretching), 2369 (Aromatic 
C=N stretching), 1653 (C=O stretching), 1457 
(Aromatic C=C stretching), 1129 (Aromatic 
C-C stretching) and 755 cm-1 (Aromatic C-N 
Stretching). 
In 1HNMR spectrum different peaks at particular 
value signified specific proton couplings. A 
broad singlet at δ 1.17 ppm denotes nine protons 
of tert-butyl. Further, singlets appeared at δ 
3.61 ppm and δ 3.79 ppm representing 9H of 
OCH3 group; again a singlet at δ 5.92 ppm may 
be assigned for NH group present in the moiety. 
A doublet was also observed at δ 4.38-4.36 ppm 
for 2H of CH2; singlet for aliphatic proton was 
appeared at δ 5.21 ppm. For all the 11 aromatic 
protons we may assign a multiplet between δ 
7.8-6.20 ppm. (Fig. 2.1)
In 13C NMR study, different peaks were 
studied and attributed to different carbon atoms 
according to the surroundings. An important 
peak at δ 165.2 verified carbonyl group of amidic 
unit in the moiety. Peaks at δ 28.4 and 29.6 
denote the methyl carbons of CH3 and OCH3 
while 52.3, 65.2 and 111.9 can be attributed 
to the CH2, CH and C respectively. Peaks at δ 
120.3, 122.8, 123.3, 124.5, 127.8, 128.8, 129.4, 
129.9, 130.1, 130.4, 133.7, 134.5, 134.6, 143.3 
and 155.1 confirmed the presence of aromatic 
carbons. (Fig. 2.2) Further, a distinctive peak 
was also detected at m/z: 488.1 in the mass 
spectral studies (Fig. 2.3), which additionally 
confirmed the formation of compound 8d. 
Based on the above spectral studies, the 
compound 8d was identified as 2-(2-benzyl-1H-
benzo [d] imidazol-1-yl)-N-tert-butyl-2-(3,4,5-
trimethoxyphenyl)acetamide (8d).
General procedure for the synthesis of imines 
(8a-8g):
Benzoic acid (1 eq.), benzaldehyde (1 eq.), Boc-
protected o-phenylenediamine (1 eq.) and tert-
Chemistry & Biology Interface Vol. 9 (4), July – August 2019220
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butyl isocyanide (1 eq.) were taken in MeOH 
(2 ml) reacted under microwave conditions 
(800 C, 15 min.). The reaction was verified 
for completion by the TLC after consecutive 
period of time, then the solvent was evaporated. 
Without purification, the intermediate was 
used under microwave conditions for further 
deprotection and cyclization in 10% TFA and 
DCE as estimated by thin layer chromatography. 
Further progress was done by neutralizing the 
whole medium by using saturated solution 
of NaHCO3. Later worked up with water and 
ethylacetate. Finally, from the reaction mixture, 
organic layer was separated, remaining mixture 
was dried over Na2SO4 later solvent was 
evaporated. Finally after crystallization, pure 
compounds 8(a-g) were obtained in good yield. 
Spectral data of compounds (8a-8g)
1. 2-(2-(2-bromophenyl)-1H-benzo[d]
imidazo l -1 -y l ) -N- t e r t -buty l -2 - (4 -
chlorophenyl) acetamide (8a): IR (KBr) 
ν: 3344, 1678, 1452, 1371, 1220, 1092, 768 
cm-1; 1H NMR (300 MHz, CDCl3): 1.28 (s, 
9H, CH3), 5.66 (s, 1H, CH), 5.92 (s, 1H, 
NH), 7.88-6.94 (m, 12H, Ar-H); 13C NMR 
(75 MHz, CDCl3): δ 29.7, 48.1, 51.6, 108.8, 
112.8, 114.6, 117.4, 119.2, 119.4, 134.7, 
134.8, 135.0, 143.0, 145.8, 146.3, 148.7, 
149.6, 151.8, 151.9, 164.6; MS (ESI) m/z: 
498.1 [M+H]+. 
2. 2-(2-bromophenyl)-N- tert-butyl-2-
(2-phenyl-1H-benzo[d]imidazol-1yl)
acetamide (8b): IR (KBr) ν: 3278, 1660, 
1638, 1565, 1219, 1150 cm-1; 1H NMR (300 
MHz, CDCl3): δ 1.31 (s, 9H, CH3), 5.50 (s, 
1H, CH), 6.24 (s, 1H, NH), 8.10-7.14 (m, 
13H, Ar-H ); 13C NMR (75 MHz, CDCl3): δ 
28.3, 60.8, 62.9, 104.8, 112.1, 119.8, 122.4, 
122.9, 127.3, 128.4, 129.1, 129.7, 134.1, 
136.2, 137.8, 136.2, 137.8, 142.7, 153.2, 
153.4, 165.8; MS (ESI) m/z: 462.2 [M+H]+.
3. N-tert-butyl-2-(4-chlorophenyl)-2-(2-
phenyl-1H-benzo[d]imidazol-1-yl)
acetamide (8c): IR (KBr)ν: 2922, 1679, 
1455, 1369, 1220, 1018, 765 cm-1; 1H NMR 
(300 MHz, CDCl3): δ 1.39 (s, 9H, CH3), 5.50 
(s, 1H, CH), 6.14 (s, 1H, NH), 8.10-7.14 (m, 
13H, Ar-H ); 13C NMR (75 MHz, CDCl3): δ 
29.3, 62.6, 64.5, 107.9, 113.3, 119.7, 123.5, 
124.1, 128.4, 130.2, 130.6, 133.9, 134.3, 
136.7, 137.2, 138.8, 141.7, 154.7, 154.9, 
166.4; MS (ESI) m/z: 418.2 (100) [M+1]+. 
4. 2-(2-benzyl-1H-benzo[d]imidazol-1-yl)-
N-tert-butyl-2-(3,4,5-trimethoxyphenyl) 
acetamide (8d): IR (KBr)ν: 3291, 2369, 
1653, 1457, 1129, 755 cm-1; 1H NMR (300 
MHz, CDCl3): δ 1.17 (s, 9H, CH3), 3.61 (s, 
6H, OCH3), 3.79 (s, 3H, OCH3), 4.38-4.36 
(d, 2H, CH2), 5.21 (s, 1H, CH), 5.92 (s, 1H, 
NH),  7.8-6.20 (m, 11H, Ar-H ); 13C NMR 
(75 MHz, CDCl3): δ 28.4, 29.6, 52.3, 65.2, 
111.9, 120.3, 122.8, 123.3, 124.5, 127.8, 
128.8, 129.4, 129.9, 130.1, 130.4, 133.7, 
134.5, 134.6, 143.3, 155.1, 165.2; MS (ESI) 
m/z: 488.1 [M+H]+. 
5. N - t e r t - b u t y l - 2 - ( 2 - p h e n y l - 1 H -
b e n z o [ d ] i m i d a z o l - 1 - y l ) - 2 - ( 3 , 4 , 5 -
trimethoxyphenyl) acetamide (8e): IR 
(KBr)ν: 3408, 1652, 1524, 1380, 1225, 
1159, 1058, 786 cm-1; 1H NMR (300 MHz, 
CDCl3): δ 1.37 (s, 9H, CH3), 1.46 (s, 9H, 
OCH3), 6.09 (s, 1H, CH), 6.38 (s, 1H, NH), 
8.55-6.86 (m, 11H, Ar-H ); 13C NMR (75 
MHz, CDCl3): δ 28.6, 29.3, 30.5, 72.7, 79.8, 
111.4, 117.6, 121.8, 123.6, 123.8, 126.7, 
130.4, 130.9, 137.1, 138.5, 140.2, 144.3, 
144.7, 148.9, 150.3, 156.6, 157.1, 164.3; 
MS (ESI) m/z: 558.1 [M+H]+. 
6. 2-(2- (1H-indol -2-y l ) -1H-benzo[d]
imidazo l -1 -y l ) -N- ter t -buty l -2 - (4 -
chlorophenyl) acetamide (8f): IR (KBr)
ν: 3426, 2366, 1638, 1220, 772, 673 cm-1; 
1H NMR (300 MHz, CDCl3): δ 1.29 (s, 9H, 
CH3), 5.58 (s, 1H, CH), 6.74 (s, 1H, NH), 
10.84-6.80 (m, 14H, Ar-H) ppm; 13C NMR 
(75 MHz, CDCl3): δ 35.3, 38.6, 39.2, 62.6, 
66.7, 106.2, 119.1, 123.3, 123.6, 129.7, 
132.4, 135.7, 136.1, 136.3, 138.5, 139.2, 
Chemistry & Biology Interface Vol. 9 (4), July – August 2019221
Chemistry & Biology Interface, 2019, 9, 4, 216-224
S.No Comp.        Hybrid        R1   R2          R3
Time
(min.)
Yield*
1 8a
N
N
O
H
N
Br
Cl
Br
Cl
15 75
2 8b N
N
O
H
N
Br
Br
15 87
3 8c
N
N
O
H
N
Cl
Cl
15 82
4 8d
N
N
O
H
N
O
O O
MeO
MeO
MeO
15 88
5 8e
N
N
O
H
N
O
O O
MeO
MeO
MeO
15 82
6 8f
N
N
O
H
N
Cl
HN
Cl
15 78
7 8g N
N
O
H
N
N
H
N
H
15 85
#boc-protected o-phenylenediamine, substituted benzoic acid, substituted benzaldehyde and tert-butyl isocyanide under micro 
wave irradiations.
*Isolated yield.
Table 1: Details of syntheses of derivatives under microwave irradiation.#
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141.6, 143.7, 143.9, 147.2, 149.8, 154.5, 
155.2, 166.1; MS (ESI) m/z: 308 [M+H]+.
7. N-tert-butyl-2-(1H-indol-3-yl)-2-(2-
phenyl-1H-benzo[d]imidazol-1-yl)
acetamide (8g): IR (KBr) ν: 3479, 2932, 
1632, 1446, 1220, 771 cm-1; 1H NMR (300 
MHz, CDCl3): 1.29 (s, 9H, CH3), 5.58 (s, 1H, 
CH), 6.74 (s, 1H, NH), 10.84-6.80 (m, 15H, 
Ar-H) ppm; 13C NMR (75 MHz, CDCl3): δ 
40.7, 42.9, 43.2, 61.2, 65.9, 117.3, 118.2, 
121.4, 125.6, 128.5, 130.8, 134.7, 138.2, 
138.6, 140.1, 142.3, 145.3, 147.7, 147.8, 
153.3, 167.3; MS (ESI) m/z: 308 [M+H]+. 
Plausible Mechanism:
For further understanding and investigation in 
the reaction we have gone through the literature 
survey and found out a plausible mechanism for 
the reaction (Scheme 2). First of all, reactivity 
of o-phenylenediamine was reduced by 
protecting one amino group by Boc. The other 
lewis basic site of o-phenylenediamine initiated 
the electrophilic activation at the aldehydic 
site which in turn enhances condensation of A 
with B to give an imine C, which was further 
activated by the lewis acidic site of acid to make 
it more electrophilic in nature. The activated 
imine C was attacked by the nucleophilic 
isocynide to form a complex D, which again 
combine with the acid to form an intermediate 
E which underwent subsequent intramolecular 
nucleophilic cyclization reaction from the 
required hybrids containing benzimidazole 
moiety.
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Scheme 2: Plausible mechanism.
BIOLOGICAL EVALUATION
Antimalarial assay: 
For augmenting the biological importance of 
the hybrids so synthesized, they were examined 
for their antimalarial activity using MSF assay 
[23-24]. In this diagnostic assay, activity is 
tested against CQ-sensitive 3D7 strain. (Table 
2) Derivatives to be examined were incubated 
for 72 hrs with insertion of 1% parasitized cell 
suspension which contained 0.8-1% initial 
parasitaemia at 370C in CO2 incubator. After 
prescribed time period, each well plate was 
injected with SYBR Green-I dye for better 
differentiation. After an hour of incubation, 
using Chloroquine (CQ) as standard, plates 
were observed for excitation at 485±20nm and 
for emission at 530±20nm. For calculating 
IC50 (i.e the inhibitory concentration where 
50% of the parasitemia are suppressed) and SI 
(Selectivity Index) the procedure prescribed in 
the literature was followed. For detecting multi-
drug-resistance, P. yoelii nigeriensis was used 
as standard to show the deviation in activity 
against CQ, mefloquine and halofantrine.
Chemistry & Biology Interface, 2019, 9, 4, 216-224
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Table 2: Antimalarial ‘in vitro’ activity of 
benzimidazole derivatives. 
Comp. no.
Antimalarial 
activity 3D7
IC50 (ng/mL)a
Selectivity
Index (SI) 
8a 55.45 429.15
8b 16.69 288.28
8c 32.41 1051.51
8d 11.25 89.6
8e 313.29 57.71
8f 245.0 43.97
8g 39.15 157.9
CQ 2.45+1.03 75.000
a (IC50) inhibitory concentration for 50% suppression of the 
parasitemia. 
All benzimidazole derivatives showed 
moderate to good antimalarial activity when 
compared with chloroquine as reference 
compound. Among these compounds (8b), (8c) 
and (8d) were found to be more potent towards 
antimalarial activity. By SAR (Structure 
Activity Relationship) analysis, we may predict 
that the antimalarial activity is enhanced by the 
electronegative groups like methoxy, chloro, 
and bromo. The CH2 group of the benzyl moiety 
further boost the reactivity. Thus, we can say 
that benzimidazole nucleus possess immense 
potential to be optimized for the generation of 
novel, secure, and more effecient drugs that 
can assure the increasing requirement of more 
potent therapeutic agent. 
Conclusions
In summary, a series of novel benzimidazole 
derivatives was designed, synthesized via post 
Ugi MCR and evaluated as antimalarial activity. 
The results showed that most of synthesized 
compounds exhibited moderate to high 
antimalarial activities against 3D7 cell line. 
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